| Literature DB >> 33790677 |
Shengwei Wang1, Hao Cui2, Keshan Ji3, Changsheng Zhu4, Xiaohong Huang3, Yongqiang Lai1, Shuiyun Wang4.
Abstract
PURPOSE: Obstructive sleep apnea (OSA) and myocardial fibrosis are associated with cardiac arrhythmia. The purpose of this study was to explore the relationship between OSA and myocardial fibrosis, as well as their impact on cardiac arrhythmia in hypertrophic obstructive cardiomyopathy (HOCM) patients.Entities:
Keywords: cardiac arrhythmia; hypertrophic obstructive cardiomyopathy; obstructive sleep apnea
Year: 2021 PMID: 33790677 PMCID: PMC8006971 DOI: 10.2147/NSS.S270684
Source DB: PubMed Journal: Nat Sci Sleep ISSN: 1179-1608
Baseline Characteristics of the Study Population
| Variable | None OSA (n=67) | Mild OSA (n=45) | Moderate OSA (n=24) | Severe OSA (n=15) | p |
|---|---|---|---|---|---|
| Age, years | 43.7±14.4 | 54.44±11.2 | 55.6±11.6 | 49.3±11.1 | <0.001 |
| Male | 41 (61.2%) | 26 (57.8%) | 15 (62.5%) | 11 (73.3%) | 0.650 |
| Body mass index, kg/m2 | 24.2±2.7 | 25.0±3.1 | 24.7±2.7 | 26.1±2.6 | 0.099 |
| Family history of HCM or SCD | 18 (26.9%) | 5 (11.1%) | 3 (12.5%) | 1 (6.7%) | 0.023 |
| NYHA class | 2.8±0.5 | 2.7±0.4 | 2.8±0.4 | 2.7±0.6 | 0.681 |
| Fasting blood glucose, mmol/L | 4.4±0.7 | 4.8±0.8 | 5.0±1.2 | 5.6±2.3 | <0.001 |
| BNP, pg/mL | 1400 (581.9–2116) | 1189 (521.8–2707) | 1181 (481.7–1755) | 1444 (652.2–2116) | 0.895 |
| Norepinephrine, ng/mL | 0.28±0.05 | 0.31±0.08 | 0.34±0.12 | 0.38±0.09 | <0.001 |
| Clinical presentation | |||||
| Chest pain | 17 (25.4%) | 8 (17.8%) | 9 (37.5%) | 6 (40.0%) | 0.195 |
| Amaurosis | 10 (15.2%) | 7 (15.6%) | 3 (15.2%) | 2 (13.3%) | 0.985 |
| History of syncope | 8 (11.9%) | 7 (15.6%) | 6 (25.0%) | 7 (46.7%) | 0.013 |
| Medical therapy | |||||
| Beta-blockers | 44 (65.7%) | 34 (75.6%) | 15 (62.5%) | 11 (73.3%) | 0.604 |
| Calcium-channel blockers | 10 (14.9%) | 8 (17.8%) | 1 (4.2%) | 3 (20.0%) | 0.175 |
| Concomitant disease | |||||
| Diabetes mellitus | 3 (4.5%) | 3 (6.7%) | 1 (4.2%) | 2 (13.3%) | 0.594 |
| Hypertension | 7 (10.4%) | 11 (24.4%) | 5 (20.8%) | 3 (20.0%) | 0.250 |
| Apnea hypopnea index, 1/h | 1.5±1.3 | 8.3±2.7 | 20.7±4.2 | 43.7±14.6 | <0.001 |
| Oxygen desaturation index, 1/h | 2.6 (1.0–6.3) | 8.6 (6.5–11.1) | 17.7 (12.6–23.8) | 36.7 (27.3–50.6) | <0.001 |
| Lowest SpO2, % | 83.5±8.4 | 81.4±9.4 | 77.7±8.0 | 71.5±8.4 | <0.001 |
| Time ratio of SpO2 <90%, % | 0.7 (0.0–12.9) | 1.4 (0.5–7.4) | 10.3 (2.5–15.3) | 27.1 (13.5–52.3) | 0.001 |
| Total sleep time, min | 529.7±99.1 | 527.4±108.6 | 504.6±78.1 | 520.6±86.7 | 0.743 |
Abbreviations: OSA, obstructive sleep apnea; HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; NYHA, New York Heart Association; BNP, brain natriuretic peptide; LVEDD, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; LVOT, left ventricular outflow tract; LVEF, left ventricular ejection fraction; SpO2, oxygen saturation.
Imaging Parameters of the Study Population
| Variable | None OSA (n=67) | Mild OSA (n=45) | Moderate OSA (n=24) | Severe OSA (n=15) | p |
|---|---|---|---|---|---|
| Echocardiographic indices | |||||
| LVEF, % | 67.9±6.0 | 67.8±5.7 | 68.5±6.2 | 67.3±6.8 | 0.940 |
| Left atrial diameter, mm | 42.9±6.7 | 44.9±5.9 | 44.8±7.6 | 47.9±7.7 | 0.063 |
| LVEDD, mm | 40.5±3.9 | 42.6±4.6 | 44.3±4.1 | 45.7±4.9 | <0.001 |
| IVST, mm | 21.6±5.6 | 20.8±4.1 | 19.8±3.4 | 21.4±3.8 | 0.453 |
| LVOT gradient, mmHg | 69.7±24.4 | 72.5±21.3 | 75.7±27.3 | 74.5±23.4 | 0.711 |
| LVOT obstruction at rest | 49 (73.1%) | 35 (77.8%) | 21 (87.5%) | 14 (93.3%) | 0.041 |
| Pulmonary hypertension | 6 (9.0%) | 7 (15.6%) | 2 (8.3%) | 2 (13.3%) | 0.692 |
| Cardiac magnetic resonance | |||||
| Indexed LV mass, g/m2 | 93.9±27.1 | 90.5±23.9 | 95.0±29.2 | 126.3±56.0 | 0.001 |
| Indexed LV volume, mL/m2 | 88.6±28.9 | 86.5±23.0 | 93.5±31.3 | 115.4±52.6 | 0.014 |
| Indexed LGE mass, g/m2 | 5.9 (3.5–10.4) | 5.6 (3.1–8.3) | 9.3 (5.2–13.5) | 14.0 (10.7–23.3) | 0.038 |
| Indexed LGE volume, mL/m2 | 5.6 (3.3–9.9) | 5.4 (2.9–7.9) | 8.8 (5.0–12.8) | 13.4 (10.2–22.2) | 0.032 |
| LGE, % of LV mass | 6.1 (3.4–10.0) | 6.8 (3.6–12.9) | 9.6 (5.5–14.5) | 15.5 (9.3–20.0) | 0.003 |
Abbreviations: OSA, obstructive sleep apnea; VEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; LVOT, left ventricular outflow tract; LGE, late gadolinium enhancement.
Figure 1Representative LGE and non-sustained ventricular tachycardia image from patients. (A, B) The 4-chamber long-axis and left ventricular short-axis image from a patient who have severe OSA with a value of 13.99%LGE (arrow); (C) the representative non-sustained ventricular tachycardia image from the same patient; (D–E) the 4-chamber long-axis and left ventricular short-axis image from a patient who have severe OSA with a value of 21.88%LGE (arrow).
Clinical Variables Associated with LGE% from Univariate and Multivariate Analysis
| Variable | Univariate | Multivariate Adjusted R2=0.264 | ||
|---|---|---|---|---|
| r | p | β | p | |
| Age | −0.025 | 0.751 | ||
| Sex | −0.177 | 0.021 | ||
| History of syncope | 0.159 | 0.040 | ||
| NYHA class | 0.211 | 0.006 | 0.174 | 0.018 |
| Left atrial diameter | 0.142 | 0.066 | ||
| IVST | 0.161 | 0.037 | 0.163 | 0.026 |
| Apnea hypopnea index, 1/h | 0.278 | <0.001 | 0.286 | <0.001 |
| Oxygen desaturation index, 1/h | 0.247 | 0.001 | ||
| Time ratio of SpO2 <90%, % | 0.163 | 0.034 | ||
Abbreviations: LGE, late gadolinium enhancement; NYHA, New York Heart Association; IVST, interventricular septal thickness.
Relationship Between Arrhythmias and OSA
| Variable | None OSA (n=67) | Mild OSA (n=45) | Moderate OSA (n=24) | Severe OSA (n=15) | p |
|---|---|---|---|---|---|
| Isolated PVC | 4 (6.0%) | 11 (24.4%) | 6 (25.0%) | 7 (46.7%) | 0.028 |
| Paired PVC | 13 (19.4%) | 13 (28.9%) | 11 (45.8%) | 7 (46.7%) | 0.036 |
| Ventricular bigeminy | 6 (9.0%) | 11 (24.4%) | 5 (20.8%) | 7 (46.7%) | 0.005 |
| Ventricular trigeminy | 3 (4.5%) | 6 (13.3%) | 6 (25.0%) | 7 (46.7%) | <0.001 |
| NSVT | 8 (11.9%) | 7 (15.6%) | 8 (33.3%) | 8 (53.3%) | 0.001 |
| Isolated PAC | 9 (13.4%) | 7 (15.6%) | 8 (33.3%) | 6 (40.0%) | 0.032 |
| Paired PAC | 20 (29.9%) | 21 (46.7%) | 7 (29.2%) | 7 (46.7%) | 0.211 |
| Atrial bigeminy | 8 (11.9%) | 9 (20.0%) | 3 (12.5%) | 6 (40.0%) | 0.060 |
| Atrial trigeminy | 6 (9.0%) | 4 (8.9%) | 1 (4.2%) | 2 (13.3%) | 0.791 |
| SVT | 14 (20.9%) | 18 (40.0%) | 10 (41.7%) | 8 (53.3%) | 0.029 |
| Atrial fibrillation | 6 (9.0%) | 9 (20.0%) | 7 (29.2%) | 3 (20.0%) | 0.045 |
| Sinus arrest | 5 (7.5%) | 5 (11.1%) | 3 (12.5%) | 1 (6.7%) | 0.835 |
| Ectopic beat | 0 (0.0%) | 1 (2.2%) | 1 (4.2%) | 0 (0.0%) | 0.413 |
Abbreviations: OSA, obstructive sleep apnea; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; PAC, premature atrial contraction; SVT, supraventricular tachycardia.
Figure 2The value of late gadolinium enhancement according to the presence of various arrhythmias between patients with and without arrhythmias. (A) Premature ventricular contractions; (B) paired premature ventricular contractions; (C) ventricular bigeminy; (D) ventricular trigeminy; (E) premature atrial contractions; (F) atrial bigeminy; (G) non-sustained ventricular tachycardia; (H) supraventricular tachycardia.
Adjusted Logistic Regression Among Arrhythmias and Significant Variables from Univariate Analysis
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| Apnea hypopnea index, 1/h | 1.05 (1.02–1.08) | 0.001 | 1.04 (1.008–1.08) | 0.001 |
| LGE, % of LV mass | 1.06 (1.004–1.12) | 0.037 | 1.07 (1.004–1.15) | 0.039 |
| LGE, % of LV mass | 1.06 (1.01–1.12) | 0.0.16 | 1.06 (1.004–1.11) | 0.034 |
| Glucose | 1.68 (1.12–2.50) | 0.012 | 1.67 (1.11–2.49) | 0.014 |
| Apnea hypopnea index | 1.04 (1.01–1.07) | 0.003 | 1.26 (1.11–1.62) | 0.002 |
| LGE % of LV mass | 1.05 (1.02–1.10) | 0.050 | 1.04 (1.01–1.07) | 0.003 |
| Male | 0.29 (0.12–0.71) | 0.007 | 0.29 (0.11–0.84) | 0.022 |
| Apnea hypopnea index | 1.06 (1.03–1.09) | <0.001 | 1.06 (1.02–1.09) | 0.001 |
| LVOT gradient | 0.98 (0.95–0.99) | 0.036 | 0.97 (0.93–0.99) | 0.035 |
| LGE % of LV mass | 1.11 (1.05–1.18) | 0.001 | 1.07 (1.003–1.15) | 0.040 |
| Male | 2.29 (1.09–4.83) | 0.030 | 3.04 (1.28–7.20) | 0.012 |
| Left atrium diameter | 1.07 (1.008–1.14) | 0.026 | 1.10 (1.03–1.18) | 0.006 |
| Apnea hypopnea index | 1.03 (1.006–1.06) | 0.017 | 1.04 (1.006–1.07) | 0.017 |
| Apnea hypopnea index | 1.08 (1.04–1.12) | <0.001 | 1.08 (1.04–1.13) | <0.001 |
| Family history of HCM or SCD | 2.89 (1.16–7.18) | 0.023 | 7.02 (1.92–25.69) | 0.003 |
| LGE % of LV mass | 1.19 (1.11–1.28) | <0.001 | 1.17 (1.09–1.26) | <0.001 |
| Age | 1.04 (1.01–1.08) | 0.005 | 1.12 (1.06–1.19) | <0.001 |
| Left atrium diameter | 1.12 (1.06–1.19) | <0.001 | 1.05 (1.01–1.08) | 0.006 |
| Apnea hypopnea index | 1.03 (1.000–1.05) | 0.05 | 1.04 (1.005–1.07) | 0.006 |
| Left atrium diameter | 1.09 (1.02–1.17) | 0.009 | 4.14 (1.33–12.93) | 0.01 |
Notes: Adjusted for age, sex, body mass index, and other relevant covariates (variables with p<0.10 on univariate analysis).
Abbreviations: PVC, premature ventricular contraction; LGE, late gadolinium enhancement; NSVT, non-sustained ventricular tachycardia; PAC, premature atrial contraction.